MKMartin Alexander Kriegel

Martin Alexander Kriegel

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Martin Alexander Kriegel has a total of 187 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Mikrobiom, Ernährung und Rheuma

    by Christina Heidt, Martin A. Kriegel

  • Open Access

    Mikrobiom, Ernährung und Rheuma

    by Christina Heidt, Martin A. Kriegel

    Zusammenfassung: Rheumatische Erkrankungen wie rheumatoide Arthritis (RA), Spondyloarthritis (SpA) und systemischer Lupus erythematodes (SLE) sind durch eine gestörte Immunregulation und persistierende Entzündungsprozesse gekennzeichnet, die eine fortschreitende Gewebeschädigung verursachen. Die Pathogenese dieser Erkrankungen ist multifaktoriell und resultiert aus einem komplexen Zusammenspiel genetischer Prädispositionen, umweltbedingter Einflüsse und immunologischer Dysregulationen. Zunehmende Evidenz weist auf die zentrale Bedeutung der intestinalen Mikrobiota und der Darmbarriere in der Krankheitsentstehung hin. Vor diesem Hintergrund rückt die Modulation der intestinalen Mikrobiota als potenzieller therapeutischer Ansatz verstärkt in den Fokus. Ernährungstherapeutische Strategien, insbesondere eine ballaststoffreiche Ernährung, könnten durch die Förderung kommensaler Bakterien sowie die gesteigerte Produktion kurzkettiger Fettsäuren (SCFAs) eine immunmodulatorische Wirkung entfalten. SCFAs, insbesondere Butyrat, stabilisieren die Integrität der Darmbarriere und wirken entzündungshemmend, indem sie regulatorische T‑Zellen (Tregs) induzieren und proinflammatorische Immunantworten dämpfen. Die gezielte Beeinflussung des Mikrobioms durch ernährungsmedizinische Interventionen ist deshalb eine vielversprechende Ergänzung zu etablierten Therapiekonzepten für rheumatische Erkrankungen.


  • Top Cited Papers

    Translocating gut pathobiont Enterococcus gallinarum induces T H 17 and IgG3 anti-RNA–directed autoimmunity in mouse and human

    by Konrad Gronke, Mytien Nguyen, Helen Fuhrmann, Noemi Santamaria de Souza, Julia Schumacher, Márcia S. Pereira, Ulrike Löschberger, Anna Brinkhege, Nathalie J. Becker, Yi Yang, et al.

    Chronic autoimmune diseases often lead to long-term sequelae and require lifelong immunosuppression because of an incomplete understanding of the triggers and drivers in genetically predisposed patients. Gut bacteria that escape the gut barrier, known as translocating gut pathobionts, have been implicated as instigators and perpetuators of extraintestinal autoimmune diseases in mice. The gut microbial contributions to autoimmunity in humans remain largely unclear, including whether specific pathological human adaptive immune responses are triggered by such pathobionts. Here, we show that the translocating pathobiont Enterococcus gallinarum can induce both human and mouse interferon-γ + T helper 17 (T H 17) differentiation and immunoglobulin G3 (IgG3) subclass switch of anti– E. gallinarum RNA antibodies, which correlated with anti-human RNA autoantibody responses in patients with systemic lupus erythematosus (SLE) and autoimmune hepatitis, two extraintestinal autoimmune diseases. E. gallinarum RNA, but not human RNA, triggered Toll-like receptor 8 (TLR8), and TLR8-mediated human monocyte activation promoted human T H 17 induction by E. gallinarum . Translocation of the pathobiont triggered increased anti-RNA autoantibody titers that correlated with renal autoimmune pathophysiology in murine gnotobiotic lupus models and with disease activity in patients with SLE. These studies elucidate cellular mechanisms of how a translocating gut pathobiont induces systemic human T cell– and B cell–dependent autoimmune responses and provide a framework for developing host- and microbiota-derived biomarkers and targeted therapies in autoimmune diseases.


  • Open Access

    Human Th17- and IgG3-associated autoimmunity induced by a translocating gut pathobiont

    by Konrad Gronke, Mytien Nguyen, Noemi Santamaria, Julia Schumacher, Yi Yang, Nicole D Sonnert, Shana Leopold, Anjelica L. Martin, Remy Hallet, Kirsten Richter, et al.

    Extraintestinal autoimmune diseases are multifactorial with translocating gut pathobionts implicated as instigators and perpetuators in mice. However, the microbial contributions to autoimmunity in humans remain largely unclear, including whether specific pathological human adaptive immune responses are triggered by such pathobionts. We show here that the translocating pathobiont Enterococcus gallinarum induces human IFNγ + Th17 differentiation and IgG3 subclass switch of anti- E. gallinarum RNA and correlating anti-human RNA autoantibody responses in patients with systemic lupus erythematosus and autoimmune hepatitis. Human Th17 induction by E. gallinarum is cell-contact dependent and involves TLR8-mediated human monocyte activation. In murine gnotobiotic lupus models, E. gallinarum translocation triggers IgG3 anti-RNA autoantibody titers that correlate with renal autoimmune pathophysiology and with disease activity in patients. Overall, we define cellular mechanisms of how a translocating pathobiont induces human T- and B-cell-dependent autoimmune responses, providing a framework for developing host- and microbiota-derived biomarkers and targeted therapies in extraintestinal autoimmune diseases. One Sentence Summary: Translocating pathobiont Enterococcus gallinarum promotes human Th17 and IgG3 autoantibody responses linked to disease activity in autoimmune patients.


  • Translocating Lactobacillus torments tumors via tryptophan catabolism

    by Márcia S. Pereira, Martin A. Kriegel


  • Open Access

    Supporting the differential diagnosis of connective tissue diseases with neurological involvement by blood and cerebrospinal fluid flow cytometry

    by Michael Heming, Louisa Müller-Miny, Leoni Rolfes, Andreas Schulte-Mecklenbeck, Tobias J. Brix, Julian Varghese, Marc Pawlitzki, Hermann Pavenstädt, Martin A. Kriegel, Catharina C. Gross, et al.

    Objective: Neurological manifestations of autoimmune connective tissue diseases (CTD) are poorly understood and difficult to diagnose. We here aimed to address this shortcoming by studying immune cell compositions in CTD patients with and without neurological manifestation. Methods: Using flow cytometry, we retrospectively investigated paired cerebrospinal fluid (CSF) and blood samples of 28 CTD patients without neurological manifestation, 38 CTD patients with neurological manifestation (N-CTD), 38 non-inflammatory controls, and 38 multiple sclerosis (MS) patients, a paradigmatic primary neuroinflammatory disease. Results: We detected an expansion of plasma cells in the blood of both N-CTD and CTD compared to non-inflammatory controls and MS. Blood plasma cells alone distinguished the clinically similar entities N-CTD and MS with high discriminatory performance (AUC: 0.81). Classical blood monocytes indicated higher disease activity in systemic lupus erythematosus (SLE) patients. Surprisingly, immune cells in the CSF did not differ significantly between N-CTD and CTD, while CD4+ T cells and the CD4+/CD8+ ratio were elevated in the blood of N-CTD compared to CTD. Several B cell-associated parameters partially overlapped in the CSF in MS and N-CTD. We built a machine learning model that distinguished N-CTD from MS with high discriminatory power using either blood or CSF. Conclusion: We here find that blood flow cytometry alone surprisingly suffices to distinguish CTD with neurological manifestations from clinically similar entities, suggesting that a rapid blood test could support clinicians in the differential diagnosis of N-CTD.


  • Structural host immune-microbiota interactions

    by Ilana Lauren Brito, Martin Alexander Kriegel


  • Within-host evolution of a gut pathobiont facilitates liver translocation

    by Yi Yang, Mytien Nguyen, Varnica Khetrapal, Nicole D. Sonnert, Anjelica L. Martin, Haiwei Chen, Martin A. Kriegel, Noah W. Palm

    Gut commensal bacteria with the ability to translocate across the intestinal barrier can drive the development of diverse immune-mediated diseases1,2,3,4. However, the key factors that dictate bacterial translocation remain unclear. Recent studies have revealed that gut microbiota strains can adapt and evolve throughout the lifetime of the host5,6,7,8,9, raising the possibility that changes in individual commensal bacteria themselves over time may affect their propensity to elicit inflammatory disease. Here we show that within-host evolution of the model gut pathobiont Enterococcus gallinarum facilitates bacterial translocation and initiation of inflammation. Using a combination of in vivo experimental evolution and comparative genomics, we found that E. gallinarum diverges into independent lineages adapted to colonize either luminal or mucosal niches in the gut. Compared with ancestral and luminal E. gallinarum, mucosally adapted strains evade detection and clearance by the immune system, exhibit increased translocation to and survival within the mesenteric lymph nodes and liver, and induce increased intestinal and hepatic inflammation. Mechanistically, these changes in bacterial behaviour are associated with non-synonymous mutations or insertion–deletions in defined regulatory genes in E. gallinarum, altered microbial gene expression programs and remodelled cell wall structures. Lactobacillus reuteri also exhibited broadly similar patterns of divergent evolution and enhanced immune evasion in a monocolonization-based model of within-host evolution. Overall, these studies define within-host evolution as a critical regulator of commensal pathogenicity that provides a unique source of stochasticity in the development and progression of microbiota-driven disease.